药物临床试验前置伦理审查实践回顾与思考OA
Review and reflection on the practice of pre-ethical review for drug clinical trials
目的 梳理某三甲医院药物临床试验的前置伦理审查情况,总结实践经验,为前置伦理审查提供参考.方法 对 2018-2023 年某医院前置伦理项目的伦理审查进行回顾性分析.结果 某三甲医院2018-2023 年共审查前置伦理项目 285 项,其中作为牵头单位的项目 79 项,279 项临床试验最终获得伦理审查委员会的批准,6 个项目因申办者拒绝修改研究方案而未获得伦理审查委员会的批准.试验分期中Ⅲ期临床试验项目数最多,项目数最多的科室为肿瘤中心.2023 年申请前置伦理审查项目从受理到拿到批件平均耗时 43 个自然日,较其他项目耗时多 3 个自然日.2023 年某三甲医院共有前置伦理审查项目 75 项,作为参与单位的项目有 58 项,其中 42 项批准时间晚于牵头单位;9 项批准时间早于牵头单位伦理批件时间.2023 年某三甲医院申请前置伦理审查项目中有 70 项获得国家药品监督管理局药物临床试验通知书,5 项由于未取得伦理批件或未继续开展,获得通知书情况不明,获得批准通知书的项目中有 16 项被批注"临床试验需加强关注事宜",7 项需完善方案.结论 某三甲医院多项举措优化前置伦理审查管理,该审查模式不会降低伦理审查质量,有助于加速临床试验的启动.值得注意的是,构建以患者为中心的药物研发体系至关重要,在该理念指导下的临床试验符合伦理价值,为临床试验的顺利开展奠定基础,助力药物研发进程,保障患者用药需求.
Objective:To sort out the pre-ethical review status of drug clinical trials in a tertiary A hospital,summarize practical experience,and provide references for pre-ethical review.Method:A retrospective analysis was conducted on the ethical review of pre-ethical projects in a tertiary A hospital from 2018 to 2023.Results:From 2018 to 2023,a total of 285 pre-ethical projects were reviewed in this tertiary hospital,including 79 projects where it served as the leading unit.Among these,279 clinical trials ultimately received approval of the ethical review committee,while 6 projects were not approved due to sponsors'refusal to modify study protocols.In terms of trial phases,phase III clinical trials constituted the largest proportion,and the oncology center was the department with the highest number of projects.In 2023,the average time for pre-ethical review projects from submission to approval was 43 calendar days,3 days longer than for other project types.In 2023,this hospital reviewed 75 pre-ethical review projects,including 58 where it served as a participating unit.Among these,42 projects received approval later than the leading unit,while 9 projects were approved earlier than the leading unit's ethical approval date.Among the pre-ethical review projects applied in 2023,70 projects obtained drug clinical trial notifications from the National Medical Products Administration,while 5 projects had unknown notification status due to the lack of ethical approval or discontinuation.Of the projects receiving approval notifications,16 were annotated with matters requiring enhanced attention during clinical trials,and 7 necessitated protocol improvements.Conclusion:This tertiary A hospital has implemented multiple measures to optimize the management of pre-ethical review.This ethical review model does not compromise the quality of ethical review and contributes to accelerating the initiation of clinical trials.Notably,it is crucial to construct a patient-centered drug development system.Clinical trials guided by this concept align with ethical values,laying the foundation for the smooth conduct of clinical trials,assisting in the drug development process,and safeguarding patients'medication needs.
侯敏;史小媛;孙荣国;刘芳;陈蕾;左泽锦
四川大学华西医院临床研究管理部,四川 成都 610041四川大学华西医院临床研究管理部,四川 成都 610041四川大学华西医院临床研究管理部,四川 成都 610041四川大学华西医院临床研究管理部,四川 成都 610041四川大学华西医院院长办公室,四川 成都 610041四川大学华西医院临床研究管理部,四川 成都 610041
医药卫生
药物临床试验前置伦理审查伦理审查审查效率
drug clinical trialpre-ethical reviewethical reviewreview efficiency
《中国医学伦理学》 2026 (5)
594-600,7
评论